US pharmaceutical company Merck has successfully completed a late-stage trial for its Keytruda drug, which has enabled patients with oesophageal cancer to live longer. Brendan McDermid/File Photo (Reuters) - Merck & Co’s Keytruda, a PD-1 inhibitor that blocks a tumour's ability to avoid detection by cancer-fighting cells, is already approved for the treatment of several cancers, including skin and lung cancer. The trial, called KEYTRUDA (ketogenic diet plus exercise), was designed as an alternative therapy in combination with chemotherapy.
US pharmaceutical company Merck has successfully completed a late-stage trial for its Keytruda drug, which has enabled patients with oesophageal cancer to live longer. Keytruda, a PD-1 inhibitor that blocks a tumour's ability to avoid detection by cancer-fighting cells, is already approved for the treatment of several cancers, including skin and lung cancer. The trial, called KEYTRUDA (ketogenic diet plus exercise), was designed as an alternative therapy in combination with chemotherapy.